Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Adverum Biotechnologies Inc (ADVM)

Adverum Biotechnologies Inc (ADVM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 166,886
  • Shares Outstanding, K 20,757
  • Annual Sales, $ 3,600 K
  • Annual Income, $ -117,170 K
  • 60-Month Beta 0.89
  • Price/Sales 47.57
  • Price/Cash Flow N/A
  • Price/Book 0.94
Trade ADVM with:

Options Overview Details

View History
  • Implied Volatility 118.55% ( +118.55%)
  • Historical Volatility 46.56%
  • IV Percentile 16%
  • IV Rank 11.96%
  • IV High 841.56% on 11/29/23
  • IV Low 20.33% on 05/10/24
  • Put/Call Vol Ratio 1.90
  • Today's Volume 116
  • Volume Avg (30-Day) 160
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 4,302
  • Open Int (30-Day) 4,781

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -1.27
  • Number of Estimates 3
  • High Estimate -1.22
  • Low Estimate -1.31
  • Prior Year -3.10
  • Growth Rate Est. (year over year) +59.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.85 +2.42%
on 05/17/24
11.87 -32.27%
on 04/23/24
-3.31 (-29.16%)
since 04/17/24
3-Month
7.85 +2.42%
on 05/17/24
22.40 -64.11%
on 02/22/24
-12.26 (-60.39%)
since 02/16/24
52-Week
7.40 +8.65%
on 12/29/23
29.70 -72.93%
on 02/08/24
+0.14 (+1.71%)
since 05/17/23

Most Recent Stories

More News
Adverum Biotechnologies: Q1 Earnings Snapshot

Adverum Biotechnologies: Q1 Earnings Snapshot

ADVM : 8.04 (-2.55%)
Adverum Biotechnologies: Q4 Earnings Snapshot

Adverum Biotechnologies: Q4 Earnings Snapshot

ADVM : 8.04 (-2.55%)
Adverum Biotechnologies: Q3 Earnings Snapshot

Adverum Biotechnologies: Q3 Earnings Snapshot

ADVM : 8.04 (-2.55%)
Adverum Biotechnologies: Q2 Earnings Snapshot

Adverum Biotechnologies: Q2 Earnings Snapshot

ADVM : 8.04 (-2.55%)
Adverum Biotechnologies: Q1 Earnings Snapshot

Adverum Biotechnologies: Q1 Earnings Snapshot

ADVM : 8.04 (-2.55%)
Is Adial Pharmaceuticals (ADIL) Stock Outpacing Its Medical Peers This Year?

Here is how Adial Pharmaceuticals, Inc. (ADIL) and Adverum Biotechnologies (ADVM) have performed compared to their sector so far this year.

ADIL : 1.5500 (+9.93%)
ADVM : 8.04 (-2.55%)
Rumble, Braze rise; Virgin Orbit, Sientra fall

Stocks that traded heavily or had substantial price changes Friday: Rumble, Braze rise; Virgin Orbit, Sientra fall

ADVM : 8.04 (-2.55%)
SIEN : 0.1740 (-18.69%)
BB.TO : 4.02 (-2.66%)
NKLA : 0.5349 (-2.67%)
Adverum Biotechnologies: Q4 Earnings Snapshot

Adverum Biotechnologies: Q4 Earnings Snapshot

ADVM : 8.04 (-2.55%)
Adverum Biotechnologies: Q3 Earnings Snapshot

Adverum Biotechnologies: Q3 Earnings Snapshot

ADVM : 8.04 (-2.55%)
Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study

Adverum (ADVM) initiates dosing in the phase II LUNA study, currently investigating its lead product candidate ixoberogene soroparvovec for wet age-related macular degeneration.

REGN : 982.29 (+1.48%)
DVAX : 11.11 (-1.51%)
BAYRY : 7.8300 (+0.77%)
ADVM : 8.04 (-2.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum's core capabilities include clinical development,...

See More

Key Turning Points

3rd Resistance Point 8.86
2nd Resistance Point 8.62
1st Resistance Point 8.33
Last Price 8.04
1st Support Level 7.80
2nd Support Level 7.56
3rd Support Level 7.27

See More

52-Week High 29.70
Fibonacci 61.8% 21.18
Fibonacci 50% 18.55
Fibonacci 38.2% 15.92
Last Price 8.04
52-Week Low 7.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar